WuXi Biologics Included in Multiple Hang Seng Sustainability Indexes
WuXi Biologics has again been included in several Hang Seng sustainability indexes, including the ESG 50 and Corporate Sustainability Benchmark. The inclusion signifies continued recognition of the company's environmental, social, and governance (ESG) performance.
WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has once again been selected for inclusion in multiple Hang Seng sustainability indexes. The company was named to both the Hang Seng ESG 50 Index and the Hang Seng Corporate Sustainability Benchmark Index, underscoring its ongoing performance in environmental, social, and governance (ESG) matters.
The Hang Seng Indexes Company, with assessments conducted by the independent Hong Kong Quality Assurance Agency (HKQAA), evaluates the sustainability performance of listed companies annually. The framework assesses environmental, social, and governance factors relevant to specific industries. WuXi Biologics achieved an A+ rating in the HKQAA assessment, a high mark for its sustainability efforts.
WuXi Biologics views sustainability as a cornerstone of its business strategy and operations, focusing on advancing green biologics research, development, and manufacturing. Through technological innovation, lean management, and digital capabilities, the company aims to enhance resource efficiency and operational resilience.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of the ESG Committee, stated that the index inclusion reflects strong recognition of the company's long-standing commitment to sustainability. He emphasized that sustainability drives not only business growth but also industry innovation and shared value creation. WuXi Biologics intends to continue creating lasting value for its stakeholders through responsible operations.